Post-approval studies (Phase 4)Study completedNCT06633835
What this trial is testing
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
Who this might be right for
COVID-19Vaccine-Preventable DiseasesSARS CoV 2 Infection
Novavax 660